The trajectory of companies tied to the drug's legacy presents a intricate investment scenario . While the initial boom generated substantial returns , generic alternatives have significantly impacted sales https://fellowfavorite.com/story23011687/copyright-s-flagship-product-and-big-pharma-a-risky-investment